证券代码：300246 证券简称：宝莱特 公告编号：2025-058 债券代码：123065 债券简称：宝莱转债 广东宝莱特医用科技股份有限公司 关于宝莱转债 2025 年付息的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、"宝莱转债"（债券代码：123065）将于 2025 年 9 月 4 日支付第五年利息， 每 10 张"宝莱转债"（面值 1,000 元）利息为 25.00 元（含税）。 8、下一付息期起息日：2025 年 9 月 4 日 广东宝莱特医用科技股份有限公司（以下简称"公司"）于 2020 年 9 月 4 日 向不特定对象发行的可转换公司债券将于 2025 年 9 月 4 日支付 2024 年 9 月 4 日至 2025 年 9 月 3 日的利息。根据公司《创业板向不特定对象发行可转换公司 债券募集说明书》（以下简称"《募集说明书》"）有关条款的规定，现将本次付 息有关事项公布如下： 一、可转债基本情况 债券代码：123065 债券简称：宝莱转债 2、债权登记日：2025 年 9 月 3 日 3、除息日：2025 年 9 月 ...

Core Viewpoint - Guangdong Baolait Medical Technology Co., Ltd. recently engaged in in-depth discussions with three institutions regarding its business, performance, and new products [1] Group 1: Company Overview - Baolait has been focused on the research, production, and sales of medical devices since its establishment in 1993, being one of the earliest domestic manufacturers of medical monitors [3] - The company has received several accolades, including being recognized as a "National Multi-parameter Monitor Industrialization Base" and a "National Manufacturing Single Champion Enterprise" [3] - Its monitoring equipment is utilized in thousands of medical institutions, with a diverse product range in life information and support, as well as a comprehensive layout in the renal medical field [3] Group 2: Performance Summary - In the first half of 2025, Baolait reported an operating income of 523.44 million yuan, a year-on-year decrease of 2.43%, while net profit reached 1.31 million yuan, a significant increase of 152.22% [4] - Total assets amounted to 2.41 billion yuan, down 3.66% from the beginning of the period, and shareholders' equity was 1.22 billion yuan, up 0.25% [4] - The health monitoring segment saw revenues of 111.95 million yuan, down 16.01%, while the blood purification segment reported revenues of 405.70 million yuan, an increase of 1.79% [4] Group 3: New Products and Market Strategy - Baolait has launched new products such as the peritoneal dialysis machine and showcased the visual laryngoscope and enteral nutrition pump at CMEF in the first half of 2025 [4] - The "old-for-new" policy is expected to boost demand for monitoring devices, particularly benefiting mid-to-high-end products, while also facilitating equipment upgrades in the blood purification business [4] - The company has begun expanding its overseas sales of blood purification products, with overseas revenue growing by 121.29% in the first half of 2025 [4] Group 4: Future Focus - In 2025, Baolait aims to concentrate on its two main businesses, leveraging opportunities in new medical infrastructure, and developing high-margin intelligent IoT products [4] - The company plans to optimize its blood purification consumables supply chain and operational efficiency to enhance product penetration [4]

Company Overview - Founded in 1993, Baolait Medical Technology Co., Ltd. specializes in the R&D, production, and sales of medical devices, particularly monitoring equipment [1] - Recognized as a national industrialization base for multi-parameter monitors and a national champion in manufacturing [1] - Products are widely used in thousands of medical institutions across various settings, including general wards, emergency rooms, ICUs, and home healthcare [1][2] Financial Performance - In H1 2025, the company reported revenue of CNY 523.44 million, a decrease of 2.43% year-on-year [3] - Net profit attributable to shareholders was CNY 1.31 million, an increase of 152.22% year-on-year [3] - Total assets at the end of the reporting period were CNY 2.41 billion, down 3.66% from the beginning of the year [3] - The health monitoring segment saw sales of CNY 111.95 million, down 16.01%, while the blood purification segment reported sales of CNY 405.70 million, up 1.79% [3] Product Development - Recent product launches include peritoneal dialysis machines, S-series infusion pumps, and remote monitoring devices [4][5] - The BioView C100 visual laryngoscope and S200 smart enteral nutrition pump were showcased at CMEF in H1 2025 [4][5] Market Impact and Policies - The "old-for-new" policy positively impacts the monitoring equipment business by increasing demand for updated devices [6] - The company is positioned to benefit from the expansion of grassroots medical institutions and the upgrade of blood purification centers [6] International Sales - Blood purification products have begun to penetrate overseas markets, with a 121.29% increase in overseas revenue in H1 2025 [7] Competitive Advantages - The D800 series of blood dialysis devices feature integrated monitoring capabilities and IoT systems, enhancing operational efficiency and patient care [8][9] - The D800Plus model is the first domestic three-pump device capable of mixed dilution dialysis, improving treatment outcomes [9] Regulatory Developments - New policies from the National Medical Insurance Administration include monitoring parameters in dialysis pricing, which aligns with the capabilities of the D800 series [10] Patient Demographics - As of 2024, the number of patients undergoing hemodialysis is approximately 1.027 million, maintaining a compound annual growth rate of about 12% over the past decade [11] - Patients typically require dialysis treatment three times a week [11] Strategic Focus for 2025 - The company aims to focus on high-end, intelligent, and IoT-enabled products while enhancing the penetration of high-margin products in critical care and anesthesia [12] - Plans to leverage national production bases and embrace centralized procurement policies to improve operational efficiency and product availability [12][13]

Group 1 - The company has completed the industrial and commercial change registration, increasing its registered capital to 264.5759 million yuan [2] - The company's business scope has been expanded to include technical services and technical development [2] - The company's name has been changed to Guangdong Baolait Medical Technology Co., Ltd., with Yan Jinyuan as the legal representative [2]

Core Viewpoint - The financial performance of Baolait (300246) shows a mixed trend with a slight decrease in revenue but a significant increase in net profit, indicating potential areas for investment analysis [1] Financial Performance - As of the latest mid-year report, Baolait reported total revenue of 523 million yuan, a year-on-year decrease of 2.43% [1] - The net profit attributable to shareholders was 1.31 million yuan, reflecting a year-on-year increase of 152.22% [1] - The non-recurring net profit was 16.47 million yuan, which represents a year-on-year decrease of 6.80% [1] - The current ratio is 2.188, the quick ratio is 1.724, and the debt-to-asset ratio stands at 46.18% [1] Market Activity - As of August 25, 2025, Baolait's stock closed at 9.48 yuan, with a slight increase of 0.32% [1] - The trading volume was 109,200 hands, with a total transaction amount of 104 million yuan [1] - There was a net outflow of main funds amounting to 10.00 million yuan, accounting for 9.66% of the transaction amount [1] - Large orders saw a net outflow of 7.89 million yuan, while small orders experienced a net inflow of 2.02 million yuan [1] Company Background - Baolait Medical Technology Co., Ltd. was established in 1993 and is located in Zhuhai City, focusing on research and experimental development [2] - The company has invested in 21 enterprises and participated in 977 bidding projects [2] - Baolait holds 58 trademark registrations and 330 patents, along with 179 administrative licenses [2]

证券代码：300246 证券简称：宝莱特 公告编号：2025-057 债券代码：123065 债券简称：宝莱转债 统一社会信用代码：914404006175020946 商事主体类型：其他股份有限公司（上市） 法定代表人：燕金元 成立日期：1993 年 06 月 28 日 广东宝莱特医用科技股份有限公司 关于公司完成工商变更登记的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 一、概述 广东宝莱特医用科技股份有限公司（以下简称"公司"）分别于 2025 年 7 月 16 日召开的第八届董事会第二十五次会议、2025 年 8 月 1 日召开的 2025 年第二 次临时股东大会，审议通过了《关于增加公司注册资本及修订〈公司章程〉的议 案》。具体内容详见公司于 2025 年 7 月 17 日于指定信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）披露的《关于增加注册资本及修订〈公司章程〉的 公告》（公告编号 2025-042）。 公司于近日完成了上述事项的变更登记和备案手续，并取得了珠海市市场监 督管理局发出的《登记通知书》。变更后具体登 ...

Group 1 - Baolite has experienced a decline for four consecutive trading days, with a cumulative drop of -5.33% [1] - Guangdong Baolite Medical Technology Co., Ltd. is a national high-tech enterprise engaged in the research, production, and sales of medical devices, covering three main business areas: life information and support, nephrology, and health care [1] - Jin Yuan Shun An Fund's Jin Yuan Shun An Yuan Qi Flexible Allocation Mixed Fund is among Baolite's top ten shareholders, having increased its holdings in the second quarter of this year [1] Group 2 - The Jin Yuan Shun An Yuan Qi Flexible Allocation Mixed Fund has achieved a year-to-date return of 31.54%, ranking 320 out of 2279 in its category [2] - The fund's performance over various periods includes a 2.81% increase over the past week, 3.89% over the past month, and 15.87% over the past three months [2] - The fund manager, Miao Weibin, has a background in economics from Fudan University and has held various positions in asset management prior to joining Jin Yuan Shun An Fund in October 2016 [3][4]

金融界消息 截至2025年8月19日收盘，宝莱特（300246）报收于9.79元，下跌2.0%，换手率10.3%，成 交量21.76万手，成交金额2.15亿元。 资金流向方面，今日主力资金净流出1572.14万元，占比成交额7.32%。其中，超大单净流出398.39万 元、占成交额1.85%，大单净流出1173.76万元、占成交额5.46%，中单净流出流出1390.69万元、占成交 额6.47%，小单净流入2962.84万元、占成交额13.79%。 天眼查商业履历信息显示，广东宝莱特医用科技股份有限公司，成立于1993年，位于珠海市，是一家以 从事研究和试验发展为主的企业。企业注册资本26368.3817万人民币，实缴资本26368.38万人民币。公 司法定代表人为燕金元。 通过天眼查大数据分析，广东宝莱特医用科技股份有限公司共对外投资了21家企业，参与招投标项目 970次，知识产权方面有商标信息58条，专利信息330条，此外企业还拥有行政许可179个。 来源：金融界 宝莱特最新一期业绩显示，截至2025中报，公司营业总收入5.23亿元、同比减少2.43%，归属净利润 131.34万元，同比增长152.22% ...

Core Viewpoint - Baolait's stock price closed at 9.99 yuan on August 18, 2025, down 1.48% from the previous trading day, with a trading volume of 330,852 hands and a transaction amount of 330 million yuan [1]. Group 1: Company Performance - Baolait operates in the medical device industry, focusing on the research, production, and sales of medical monitoring equipment and blood dialysis devices, widely used in hospitals and clinics [1]. - For the first half of 2025, Baolait reported total operating revenue of 523 million yuan and a net profit attributable to shareholders of 1.31 million yuan, marking a turnaround from a loss in the same period last year [1]. - The company's asset-liability ratio stands at 46.18%, showing a decrease compared to the same period last year [1]. - The net cash flow from operating activities was -24.75 million yuan, indicating an improvement from the previous year [1]. Group 2: Market Activity - On August 18, 2025, the net outflow of main funds was 27.36 million yuan, with a cumulative net outflow of 41.93 million yuan over the past five days [1].

Core Insights - Baolite (300246.SZ) reported a total operating revenue of 523 million yuan for the first half of 2025, with a net profit attributable to shareholders of 1.3134 million yuan, an increase of 3.8284 million yuan compared to the same period last year [1] Financial Performance - The company's operating cash flow showed a net outflow of 24.7465 million yuan, which is an improvement of 13.6225 million yuan compared to the same period last year [1] - The latest debt-to-asset ratio stands at 46.18%, a decrease of 1.17 percentage points from the same period last year [3] - The gross profit margin is reported at 25.50% [3] - Return on equity (ROE) is at 0.11%, an increase of 0.30 percentage points year-on-year [3] - The diluted earnings per share (EPS) is 0.01 yuan, an increase of 0.01 yuan compared to the same period last year [3] - The total asset turnover ratio is 0.21 times, remaining stable compared to the same period last year, with a year-on-year increase of 1.91% [3] - The inventory turnover ratio is reported at 1.62 times [3] Shareholder Structure - The number of shareholders is 18,400, with the top ten shareholders holding a total of 92.17 million shares, accounting for 34.84% of the total share capital [3] - The largest shareholder, Yan Jinyuan, holds 26.72% of the shares [3] - Other notable shareholders include Wang Shi (2.46%) and Shenzhen Qianhai Jiuyin Investment Fund Management Co., Ltd. (1.37%) [3]